UroGen Applauds BCAN's New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
MWN-AI** Summary
UroGen Pharma Ltd., a biotechnology firm focused on innovative treatments for urothelial and specialty cancers, has expressed support for the Bladder Cancer Advocacy Network (BCAN) following the release of its report, "The New Faces of Bladder Cancer." This national survey, which gathered insights from over 1,100 bladder cancer patients, highlights the significant psychological and procedural burdens faced by individuals diagnosed with this type of cancer.
The survey reveals that nearly 80% of respondents live with a fear of recurrence, a concern that exceeds 90% among younger patients under 50 years of age. Women specifically reported an 86% fear rate, while 87% of patients who retained their bladder also expressed ongoing anxieties about recurrence. Additionally, the report emphasizes the intense procedural demands of bladder cancer management, with many patients undergoing five or more cystoscopies—some having experienced more than 15 procedures throughout their treatment journey.
Dr. Mark Schoenberg, UroGen's Chief Medical Officer, highlighted the importance of these findings, asserting that bladder cancer is often a chronic condition characterized by recurrence and uncertainty. He emphasized that patient treatment discussions should address not just tumor management, but also long-term quality of life and emotional concerns.
Meri-Margaret Deoudes, CEO of BCAN, acknowledged UroGen's role in funding the research, stressing its value in amplifying patient voices to enhance care. The report details varied patient experiences, indicating that 47% had non-muscle invasive bladder cancer (NMIBC), while others presented with different stages, ranging from carcinoma in situ (CIS) to muscle-invasive disease (MIBC).
UroGen continues to develop therapies aimed at improving patient outcomes. More information about their initiatives can be found on their website.
MWN-AI** Analysis
UroGen Pharma Ltd.’s endorsement of the Bladder Cancer Advocacy Network (BCAN) report highlighting patient fears and procedural burdens associated with bladder cancer signals a critical juncture for investors. The findings from BCAN’s survey, which reveal that nearly 80% of bladder cancer patients fear recurrence, emphasize the chronic nature of this cancer and the extensive ongoing treatment many patients endure. For UroGen, this underscores the clinical need for innovative therapies that address both tumor management and patient quality of life.
Investors should view UroGen’s involvement and financial support of the survey as a proactive move to position itself as a leader in bladder cancer treatment. The company’s proprietary RTGel technology, focused on sustained drug release directly into the urinary tract, could gain traction as these survey results draw attention to the challenges patients face regarding repeated cystoscopies and high rates of recurrence. UroGen's existing products, already approved for recurrent low-grade non-muscle invasive bladder cancer, align well with the needs identified in the report.
Market analysts may see an uptick in interest and valuation for UroGen in light of these insights, suggesting a potential increase in stock demand as the company enhances its focus on patient-centric care. This could yield longer-term gains as UroGen expands its pipeline to include additional therapies aimed at reducing procedural burdens and recurrence risk.
In conclusion, the BCAN report highlights both a significant patient need and an opportunity for UroGen to further establish itself in the bladder cancer treatment landscape. Investors should monitor UroGen’s strategic actions in response to this report, focusing on potential innovations that could enhance patient outcomes and drive company growth in this chronic disease sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- National survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under 50
- Many respondents report undergoing five or more cystoscopies, with some experiencing more than 15 procedures
PRINCETON, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a biotechnology company dedicated to developing innovative therapies for urothelial and specialty cancers, today commended the Bladder Cancer Advocacy Network (BCAN) on its release of The New Faces of Bladder Cancer Report, a national patient-reported survey underscoring the chronic and recurrent nature of bladder cancer.
The survey, which captures the experiences of more than 1,100 bladder cancer patients across the United States, found that nearly 80% of respondents reported fear of recurrence, rising to more than 90% among patients under 50. Among women, 86% reported fear of recurrence, and among patients who retained their bladder, 87% reported ongoing concern. The report also documents the cumulative procedural burden associated with bladder cancer management, with a substantial proportion of patients reporting five or more cystoscopies and some experiencing more than 15 procedures over the course of their disease.
“These findings reinforce what patients and clinicians experience every day — bladder cancer is often a chronic condition defined by recurrence, repeated procedures, and persistent uncertainty,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “When patients face years of surveillance and intervention, treatment discussions must consider not only tumor control but also long-term quality of life, personal priorities, and emotional burden. Elevating the patient voice through data of this scale is critical to improving care.”
Survey respondents represented diverse clinical experiences across all bladder cancer stages, including 47% initially diagnosed with non-muscle invasive bladder cancer (NMIBC), 23% with carcinoma in situ (CIS), and 22% with muscle-invasive disease (MIBC), with smaller proportions reporting advanced, metastatic, or upper tract urothelial carcinoma.
“This report reflects the real burden of living with bladder cancer and the lasting impact of recurrence,” said Meri-Margaret Deoudes, Chief Executive Officer of BCAN. “We thank UroGen for supporting this research, and for helping ensure that patient voices remain central to improving care.”
UroGen provided financial support for the survey and report. BCAN independently conducted the research and maintains full ownership and authorship of the findings.
The full New Faces of Bladder Cancer report is available at: www.BCAN.org/newfaces.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product is approved to treat low-grade upper tract urothelial cancer, and our second product, is approved for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both products are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X, @UroGenPharma.
INVESTOR CONTACT:
Vincent Perrone
vincent.perrone@urogen.com
(609) 460-3588 Ext. 1093
MEDIA CONTACT:
Cindy Romano
Cindy.romano@urogen.com
(609) 460-3566 Ext. 1083
FAQ**
How does UroGen Pharma Ltd. (URGN) plan to address the nearly 80% fear of recurrence reported by bladder cancer patients in their recent survey, and what role does patient feedback play in shaping future therapies?
Considering that many respondents underwent five or more cystoscopies, what innovations is UroGen Pharma Ltd. (URGN) developing to potentially reduce procedural burden for bladder cancer patients?
What strategies is UroGen Pharma Ltd. (URGN) using to enhance the emotional well-being of patients, given the high percentage of fear of recurrence among those under 50 as highlighted in the recent survey?
How does UroGen Pharma Ltd. (URGN) intend to leverage the findings from the Bladder Cancer Advocacy Network survey to improve the long-term quality of life for bladder cancer patients undergoing chronic treatment?
**MWN-AI FAQ is based on asking OpenAI questions about UroGen Pharma Ltd. (NASDAQ: URGN).
NASDAQ: URGN
URGN Trading
-1.29% G/L:
$18.35 Last:
492,893 Volume:
$18.94 Open:
